Effect of Antiplatelet and Endothelial-Protective Drugs on Cerebral Small Vessel Disease and Retinal Health in Adults Aged 30 to 79

What this Trial Is About

Researchers are investigating cerebral small vessel disease cSVD, a common condition linked with aging that affects small blood vessels in the brain and can lead to strokes and cognitive problems. This prospective cohort study in China aims to evaluate the effects of different antiplatelet agents, including cilostazol, on cSVD and retinal blood vessels in patients with recent small subcortical infarcts or white matter hyperintensities WMH. Participants will receive antiplatelet treatments such as aspirin, clopidogrel, or a combination of cilostazol and isosorbide mononitrate. The study includes patients with either recent small subcortical infarcts or WMH graded 2-3 on the Fazekas scale. Treatments are assessed over a 6-month follow-up period to monitor their impact on brain and retinal health. During the study, participants undergo neurological assessments at baseline, 1 week, 3 months, and 6 months. Brain MRI scans are done at baseline and 6 months. Cognitive function, daily living activities, and movement disorder ratings are also evaluated. Researchers monitor for bleeding events and occurrences of ischemic stroke or transient ischemic attacks while assessing changes in retinal vasculature as the primary outcome over six months.

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases